Phase 3 Readout~month

Phase 3 Topline: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimer

Name: Phase 3 Topline: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimer
Start: 2028-07-01

July 1, 2028

Company: Cabaletta Bio, Inc. (CABA)
Drug: active
Indication: Idiopathic Inflammatory Myopathy; Dermatomyositis; Immune-Mediated Necrotizing Myopathy

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimer — CABA Phase 3 Readout | BioSniper